- Home
- HRMY vs BTSG Comparison
HRMY vs BTSG Comparison
Compare HRMY & BTSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- BTSG
- Stock Information
- Founded
- HRMY 2017
- BTSG 1974
- Country
- HRMY United States
- BTSG United States
- Employees
- HRMY N/A
- BTSG N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- BTSG
- Sector
- HRMY Health Care
- BTSG
- Exchange
- HRMY Nasdaq
- BTSG NYSE
- Market Cap
- HRMY 2.0B
- BTSG 4.1B
- IPO Year
- HRMY 2020
- BTSG 2024
- Fundamental
- Price
- HRMY $31.95
- BTSG $22.53
- Analyst Decision
- HRMY Strong Buy
- BTSG Strong Buy
- Analyst Count
- HRMY 9
- BTSG 9
- Target Price
- HRMY $54.22
- BTSG $23.50
- AVG Volume (30 Days)
- HRMY 661.5K
- BTSG 3.3M
- Earning Date
- HRMY 08-05-2025
- BTSG 08-01-2025
- Dividend Yield
- HRMY N/A
- BTSG N/A
- EPS Growth
- HRMY 13.13
- BTSG N/A
- EPS
- HRMY 2.62
- BTSG 0.29
- Revenue
- HRMY $744,852,000.00
- BTSG $11,858,835,000.00
- Revenue This Year
- HRMY $20.10
- BTSG $11.55
- Revenue Next Year
- HRMY $18.01
- BTSG $12.14
- P/E Ratio
- HRMY $12.20
- BTSG $78.00
- Revenue Growth
- HRMY 20.62
- BTSG 30.55
- 52 Week Low
- HRMY $26.47
- BTSG $10.15
- 52 Week High
- HRMY $41.61
- BTSG $25.57
- Technical
- Relative Strength Index (RSI)
- HRMY 44.85
- BTSG 54.00
- Support Level
- HRMY $31.25
- BTSG $22.48
- Resistance Level
- HRMY $32.32
- BTSG $23.78
- Average True Range (ATR)
- HRMY 0.98
- BTSG 0.70
- MACD
- HRMY -0.19
- BTSG 0.04
- Stochastic Oscillator
- HRMY 21.37
- BTSG 72.94
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About BTSG BRIGHTSPRING HEALTH SERVICES INC
BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services and others. It generates the majority of its revenue from the Pharmacy Solutions segment.